High-intensity Focused Ultrasound for the Treatment of Fibroids
article
OA: diamond
CC0
⤵ 1 in-corpus citation
Abstract
Objectives: Uterine fibroids and adenomyosis are common gynecological conditions that often require surgical treatment. Minimally invasive interventions such as ultrasound-guided high-intensity focused ultrasound (USgHIFU) are gaining popularity as they avoid surgical morbidity and conserve the uterus. We present a single-center experience on the use of USgHIFU for the treatment of fibroids and adenomyosis. Materials and Methods: This was a retrospective study of 167 patients who underwent USgHIFU for uterine fibroids and adenomyosis between July 2018 and December 2020. Relevant demographic data and pre- and post-intervention fibroid volume, symptom severity scores (SSS), and health-related quality of life (QOL) scores were collected and compared. The paired t -test or Wilcoxon signed-rank test was used to compare the difference before and after treatment. P < 0.001 was considered statistically significant. Results: One hundred and sixty-seven patients with fibroids or adenomyosis were included in this study. The mean age of the cohort was 42-year-old. USgHIFU treatment led to a reduction in mean fibroid volume, improvement in SSS, and health-related QOL scores. The average reduction in mean fibroid volume was 68% and 75% at 6 and 12 months, respectively. There was a significant reduction in SSS (46.9 [pre] vs. 15.6 [post], P < 0.001) and improvement in health-related QOL scores at 6 months (58 [pre] vs. 86 [post], P < 0.001). The re-intervention rate following USgHIFU was 7.7% and successful pregnancy post USgHIFU was reported in 6 patients. Conclusion: USgHIFU is safe and effective. In women who desire fertility or are not suitable for surgery, it is a good alternative option. It should be included in the armamentarium for the treatment of uterine fibroids and adenomyosis.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (46)
- High-intensity focused ultrasound therapy via openalex
- Pregnancy and live birth after focused ultrasound surgery for symptomatic focal adenomyosis: a case report via openalex
- Safety of ultrasound-guided ultrasound ablation for uterine fibroids and adenomyosis: A review of 9988 cases via openalex
- Short-term results of magnetic resonance imaging-guided focused ultrasound surgery for patients with adenomyosis: symptomatic relief and pain reduction via openalex
- Ultrasound-guided high intensity focused ultrasound for the treatment of gynaecological diseases: A review of safety and efficacy via openalex
- W2008487912 via openalex
- W2018917216 via openalex
- W2065078698 via openalex
- W2065685950 via openalex
- W2069142930 via openalex
- W2072489748 via openalex
- W2094437002 via openalex
- W2132448668 via openalex
- W2155119821 via openalex
- W2165581774 via openalex
- W2321208332 via openalex
- W2345399665 via openalex
- W2403292935 via openalex
- W2405700978 via openalex
- W2409117511 via openalex
- W2762721460 via openalex
- W2763783086 via openalex
- W2780262866 via openalex
- W2793818040 via openalex
- W2942310428 via openalex
- W2972780066 via openalex
- W2983589030 via openalex
- W2986463097 via openalex
- W3003134026 via openalex
- W3019646576 via openalex
- W3035733632 via openalex
- W3046544337 via openalex
- W3084186137 via openalex
- W3158056549 via openalex
- W3172746379 via openalex
- W3186632188 via openalex
- W3195192127 via openalex
- W4210432364 via openalex
- W4210514411 via openalex
- W6649372403 via openalex
- W198948752 via openalex
- W6650998705 via openalex
- W628796965 via openalex
- W1894294845 via openalex
- W1996284739 via openalex
- W2001387158 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-25T00:34:00.210715+00:00
License: CC0
· commercial use OK